Budesonide for Protein Losing Enteropathy in Patients with Fontan Circulation: A Systematic Review and Meta-Analysis

Abstract

Background:

Recent studies have shown that oral budesonide can be used to improve albumin level in patients with protein-losing enteropathy (PLE) following Fontan procedure. However, there has never been a systematic review and meta-analysis to confirm this finding. We performed a systematic review and meta-analysis to explore the therapeutic effect of budesonide in patients with PLE post-Fontan procedure.

Methods:

We searched the databases of MEDLINE and EMBASE from inception to January 2019. Included studies were published studies that evaluate albumin level before and after budesonide therapy in patients with PLE following Fontan procedure. Data from each study were combined using the random-effects model.

Results:

Five studies with 36 post-Fontan operation patients with PLE were included. In random-effects model, there was a statistically significant difference in albumin level between before and after budesonide treatment (weighted mean difference = 1.28, 95% confidence interval: 0.76-1.79). No publication bias was observed on a funnel plot and Egger test with a P value of .676.

Conclusions:

The results of this systematic review and meta-analysis show that budesonide can be used to increase albumin level in patients with PLE following Fontan operation. Further studies may focus on the impact of outcome of budesonide in this population.

Keywords

adult congenital heart disease congenital heart surgery Fontan nutrition

Get full access to this article

View all access options for this article.

References

Fontan

Baudet

. Surgical repair of tricuspid atresia. Thorax. 1971;26(3):240–248.

Rychik

. Protein-losing enteropathy after Fontan operation. Congenit Heart Dis. 2007;2(5):288–300.

Mertens

Hagler

Sauer

Somerville

Gewillig

. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE Study Group. J Thorac Cardiovasc Surg. 1998;115(5):1063–1073.

Feldt

Driscoll

Offord

, et al. Protein-losing enteropathy after the Fontan operation. J Thorac Cardiovasc Surg. 1996;112(3):672–680.

Johnson

Driscoll

O’Leary

. Protein-losing enteropathy and the Fontan operation. Nutr Clin Pract. 2012;27(3):375–384.

Gursu

Varan

Erdogan

. Use of oral budesonide in the management of protein-losing enteropathy due to restrictive cardiomyopathy. Cardiol Young. 2014;24(4):764–746.

John

Driscoll

Warnes

Phillips

Cetta

. The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation. Ann Thorac Surg. 2011;92(4):1451–1456.

Schumacher

Cools

Goldstein

, et al. Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients. Pediatr Cardiol. 2011;32(7):966–971.

Thacker

Patel

Dodds

, et al. Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation. Ann thoracic surg. 2010;89(3):837–842.

10.

Turner

Lanford

Webber

. Oral budesonide as a therapy for protein-losing enteropathy in patients having undergone Fontan palliation. Congenit Heart Dis. 2012;7(1):24–30.

11.

Stang

. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.

12.

Herrmann

Brown

. The superior cavopulmonary connection: history and current perspectives. World J Pediatr Congenit Heart Surg. 2019;10(2):216–222.

13.

Gnanappa

Celermajer

Sholler

, et al. The long-term management of children and adults with a Fontan circulation: a systematic review and survey of current practice in Australia and New Zealand. Pediatr Cardiol. 2017;38(1):56–69.

14.

Gewillig

Goldberg

. Failure of the Fontan circulation. Heart Fail Clin. 2014;10(1):105–116.

15.

Fredenburg

Johnson

Cohen

. The Fontan procedure: anatomy, complications, and manifestations of failure. Radiographics. 2011;31(2):453–463.

16.

Launay

Lambert

Hachulla

, et al. Protein-losing enteropathy revealing an idiopathic constrictive pericarditis [in French]. Rev Med Interne. 2007;28(1):38–41.

17.

Levine

Kalman

Mayer

Fillit

Packer

. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323(4):236–241.

18.

Khambadkone

The Fontan pathway: what’s down the road?

Ann Pediatr Cardiol. 2008;1(2):83–92.

19.

Ostrow

Freeze

Rychik

. Protein-losing enteropathy after Fontan operation: investigations into possible pathophysiologic mechanisms. Ann thorac surg. 2006;82(2):695–700.

20.

James

Witte

Bernas

Barber

Proposal for prevention or alleviation of protein/lymph-losing enteropathy (PLE/LLE) after Fontan circulation treatment of univentricular hearts: restoration of lymph balance with a “lymphatic right-to-left shunt.”. Lymphology. 2016;49(3):114–127.

21.

Menon

Chennapragada

Ugaki

Sholler

Ayer

Winlaw

. The lymphatic circulation in adaptations to the Fontan circulation. Pediatr Cardiol. 2017;38(5):886–892.

22.

Matsuda

Ichikawa

Ueno

Sawa

. Heart transplantation for adults with congenital heart disease: current status and future prospects. Gen Thorac Cardiovasc Surg. 2017;65(6):309–320.

23.

Kanter

KR.

Heart transplantation in children after a Fontan procedure: better than people think. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2016;19(1):44–49.

24.

Peyton

. Protein-losing enteropathy and plastic bronchitis after the Fontan operation. Crit Care Nurse. 2018;38(6):e5–e12.

25.

Schumacher

Butts

, et al. Fontan-associated protein-losing enteropathy and postheart transplant outcomes: a multicenter study. J Heart Lung Transplant. 2019;38(1):17–25.

26.

Gursu

Erdogan

Varan

, et al. Oral budesonide as a therapy for protein-losing enteropathy in children after the Fontan operation. J Card Surg. 2014;29(5):712–726.

27.

John

Johnson

Khan

, et al. Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation. J Am Coll Cardiol. 2014;64(1):54–62.

28.

John

Phillips

Driscoll

Warnes

Cetta

. The use of octreotide to successfully treat protein-losing enteropathy following the Fontan operation. Congenit Heart Dis. 2011;6(6):653–666.

29.

Ryerson

Goldberg

Rosenthal

Armstrong

. Usefulness of heparin therapy in protein-losing enteropathy associated with single ventricle palliation. Am J Cardiol. 2008;101(2):248–251.

30.

Rychik

Piccoli

Barber

. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am J Cardiol. 1991;68(8):819–821.

31.

Zellers

Brown

. Protein-losing enteropathy after the modified Fontan operation: oral prednisone treatment with biopsy and laboratory proved improvement. Pediatr Cardiol. 1996;17(2):115–117.

32.

Spencer

McTavish

. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs. 1995;50(5):854–872.

33.

Campieri

Ferguson

Doe

Persson

Nilsson

. Oral budesonide is as effective as oral prednisolone in active Crohn’s disease. Global Budesonide Study Group. Gut. 1997;41(2):209–214.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB

0.02 MB